Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma.

MLA

Giusti, Massimo, et al. “Recombinant Human Thyroid Stimulating Hormone Does Not Acutely Change Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-KappaBeta Ligand in Patients under Evaluation for Differentiated Thyroid Carcinoma.” Hormones (Athens, Greece), vol. 6, no. 4, Oct. 2007, pp. 304–13. EBSCOhost, https://doi.org/10.14310/horm.2002.1111026.

APA

Giusti, M., Cecoli, F., Ghiara, C., Rubinacci, A., Villa, I., Cavallero, D., Mazzuoli, L., Mussap, M., Lanzi, R., & Minuto, F. (2007). Recombinant human thyroid stimulating hormone does not acutely change serum osteoprotegerin and soluble receptor activator of nuclear factor-kappaBeta ligand in patients under evaluation for differentiated thyroid carcinoma. Hormones (Athens, Greece), 6(4), 304–313. https://doi.org/10.14310/horm.2002.1111026

Chicago

Giusti, Massimo, Francesca Cecoli, Carla Ghiara, Alessandro Rubinacci, Isabella Villa, Domenico Cavallero, Laura Mazzuoli, Michele Mussap, Roberto Lanzi, and Francesco Minuto. 2007. “Recombinant Human Thyroid Stimulating Hormone Does Not Acutely Change Serum Osteoprotegerin and Soluble Receptor Activator of Nuclear Factor-KappaBeta Ligand in Patients under Evaluation for Differentiated Thyroid Carcinoma.” Hormones (Athens, Greece) 6 (4): 304–13. doi:10.14310/horm.2002.1111026.